Evidence map›Paper›PMID 30868287›Full record

ReviewCurrent rheumatology reports2019

The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective-an Analysis of 2846 Patients Across 13 Countries.

Marco Garrido-Cumbrera, Denis Poddubnyy, Laure Gossec, David Gálvez-Ruiz, Christine Bundy, Raj Mahapatra, Souzi Makri, Laura Christen, Carlos J Delgado-Domínguez, Sergio Sanz-Gómez and 3 more

Abstract readReview
In one paragraph

Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Marco Garrido-CumbreraUniversidad de Sevilla, Seville, Spain. mcumbrera@us.es.
Denis PoddubnyyCharité-Universitätsmedizin Berlin, Berlin, Germany.
Laure GossecSorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France.
David Gálvez-RuizUniversidad de Sevilla, Seville, Spain.
Christine BundyCardiff University, Cardiff, UK.
Raj MahapatraAnkylosing Spondylitis International Federation (ASIF), London, UK.
Souzi MakriCyprus League Against Rheumatism, Nicosia, Cyprus.
Laura ChristenNovartis Pharma AG, Patient Advocacy, Basel, Switzerland.
Carlos J Delgado-DomínguezHealth & Territory Research (HTR), Centro de Investigación, Tecnología e Innovación Manuel Losada Villasante (CITIUS), Universidad de Sevilla, C/ Dr Rafael Martínez Domínguez s/n, 41013, Seville, Spain.
Sergio Sanz-GómezUniversidad de Sevilla, Seville, Spain.
Pedro Plazuelo-RamosSpanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain.
Victoria Navarro-CompánIdiPaz, Hospital Universitario La Paz, Madrid, Spain.
EMAS Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewScientific research in axial spondyloarthritis (axSpA) has grown significantly. Nevertheless, the patient perspective remains insufficiently explored. Using a cross-sectional survey, the European Map of Axial Spondyloarthritis (EMAS) describes how patients living with self-reported axSpA experience their disease physically, psychologically, and socially. RECENT

findings2846 patients participated: mean age 43.9 ± 12.3 years, 61.3% female, mean disease duration was 17.2 ± 12.4 years, and 71.3% were HLA-B27 positive. Mean diagnostic delay was 7.4 ± 8.4 years. Mean BASDAI score was 5.5 ± 2.0 and 75.7% reported moderate/severe spinal stiffness throughout the day. Daily life was substantially impaired: 74.1% reported difficulties finding a job due to the disease, and 61.5% reported psychological distress. EMAS results showed long diagnostic delay and substantial physical and psychological burden, indicating important unmet needs for patients. Furthermore, axSpA restricted patients' ability to participate in their daily routine and lead a productive work life. Understanding the patient's perspective can improve both health outcomes and shared decision-making between patient and rheumatologist.

Indexed as

Cost of IllnessAdultDelayed DiagnosisFemaleHumansMaleMiddle AgedQuality of LifeSeverity of Illness IndexSpondylarthritisAnkylosing spondylitisAxial spondyloarthritisBurden of the diseaseEuropeNon-radiographic axial spondyloarthritisPatient’s perspectiveShared decision-making

Identifiers

PMID30868287
PMCPMC6449283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.